Amgen Inc. (AMGN)
Loading...
Symbols:
AMGN Forum Topics
- All Comments on AMGN
- General Discussion on AMGN
- 'When There's Blood in the Streets', Buy Biotech Stocks [view article]
- Hide in the Fetal Position - Fast Money Recap (10/2/08) [view article]
- Licensing Deal Is Imminent for ArQule [view article]
- Interview with Jamia Jasper, American Israeli Shared Values Capital Appreciation Fund [view article]
- Roche Covets Genentech for Good Reason [view article]
- Cancer Stocks Plunge Following ASCO Meeting [view article]
- The Dow Adds Kraft [view article]
- Court Ruling Raises Concerns About Ariad's Conduct and Patents [view article]
- Which Company Should Replace AIG in the Dow? [view article]
- Biotech Week In Review: Barron’s Touts Alzheimers Drugs From Wyeth [view article]
- Wall Street Breakfast: Must-Know News [view article]
- Which CEOs Have the Best and Worst Approval Ratings? [view article]
loading ...Recent AMGN Articles
- 'When There's Blood in the Streets', Buy Biotech Stocks
- Hide in the Fetal Position - Fast Money Recap (10/2/08)
- Licensing Deal Is Imminent for ArQule
- Court Ruling Raises Concerns About Ariad's Conduct and Patents
- Roche Covets Genentech for Good Reason
- The Dow Adds Kraft
- Which Company Should Replace AIG in the Dow?
- Putting on the Moves - Fast Money Recap (9/15/08)
- Interview with Jamia Jasper, American Israeli Shared Values Capital Appreciation Fund
- Wall Street Breakfast: Must-Know News
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Canadian
Under The Radar News - Thursday [view article]
It's old news !!!! ReplyUnder The Radar News - Thursday [view article]
Concerning: "Indian credit card issuer SBI, a joint venture between GE (GE) and State Bank of India, had a default rate of 16.28% as of year-end, likely the worst in the industry."Worse is relative: If you're invested in GE, that's GREAT News.
Reply
A "Bone Of Contention" with Amgen's Bone Drug Data? [view article]
Kevin needs to resign! Wall street, FDA, his employees, and the press do not like him for obvious reasons! ReplyEditors
General Discussion on AMGN
Is this a buy or a sell? ReplyGilead Sciences 'Pushes Out' Amgen As Number 2 Biotech [view article]
Note, I do not consider Gilead to be either a biotech or biopharmaceutical company. Biotechnology involves the use of live organisms for the manufacture of inherently biological-type products. Biotech as used here and by many others use is a vague, never defined, metaphor or reference to high-tech life sciences-based companies and research. Small molecule drugs and related R&D are neither biotech nor biopharmaceutical! Along these lines see my two-part series, "What is a Biopharmaceutical?, published in BioProcess International, with links to this at www.biopharmacopeia.co.... And, this is the approach used in my book/database, Biopharmaceutical Products in the U.S. and European Markets (see biopharma.com).Although it is incredibly common, particularly in the financial community and press, to view biotech as being based on business models (rather than marketed products, which is how industries have always been defined) and/or gee-whiz, that's neat-type views of industry, I have yet to see any usable definition or explanation of how to apply this. Most analysts I've spoken use a completely subjective 'if it seems or can be hyped as high-tech and it involves the life sciences, it's obviously biotech' approach, with just about every pharmaceutical company meeting this criteria. For this reason, just about all financial industry analyses of the biotech and biopharmaceutical industries are useless, if not misleading, including the most well-known and presumed authoritative annual reviews/studies, with criteria unset and varying depending on the year (or is it time of day, mood of the analyst, etc.) and often manipulated to meet the analyst's preconceived, often theme-based, conclusions.
As far as I am aware and I followed Gilead for 15 years, from its very start, as Editor, Antiviral Agents Bulletin, Gilead has no substantive involvement with biotechnology, with its R&D based on medicinal chemistry, and its products being synthetic small molecule drugs. Comparing Gilead to Amgen is like comparing apples and oranges--yes, they are both fruits (and pharmaceutical companies) but these companies' products, the manufacture and underlying nature (biological vs. chemical) of their products, their associated manufacturing infrastructure, the expertise of their staff, etc., are very different.
It would be accurate to say that Gilead has now overtaken Amgen as the largest non-Big Pharma-type pharmaceutical company, or the largest biotech-type company, presuming that one actually defines or makes it clear that biotech in this context involves innovative, entrepreneurial, started-from-scatch, gone from private to public-type companies.
Reply
Amgen: Lost in the Biotech Bargain Bin [view article]
Value Line indicates Amgen's net earnings per share of $3.30 In 2007 and projected earnings of $3.60 in 2008 WITH ZERO DIVIDENDS !Amgen share price is not going to move up unless they start paying some reasonable dividends of at least $1.50 per share. Reply
Amgen: Valued on Profits, Not Growth [view article]
Hmmm... where's the full disclosure? Exactly, how much is this author shorting AMGN? It looks like he has shorted the stock and now spreads all this misinformation to help him make money. Fortunately, informed readers will be turned off by the emotional vitriol in this article, and do just the opposite: buy and hold this stock. I hope this speculator loses all of his "investment" (i.e., his bets that this company will fail). ReplyFast Money Recap 3/19/08: Morgan Stanley Outshines Goldman [view article]
to Tony Soprano - very interesing, 100% agree Replywatcher
Amgen: Valued on Profits, Not Growth [view article]
You keep saying Amgen has a terrible pipeline. What about Denosumab and Vectibix? Denosumab will most likely become a blockbuster if marketed. Vectibix is on its way to 1st and 2nd line cancer treatment, which will boost current sales dramatically. ReplyAmgen: Lost in the Biotech Bargain Bin [view article]
Amgen is a very well run and conservative company but reality is market sentiment is against them now due to safety concerns about Epo, and that is one of their main revenue drivers. I believe they will see the 20s before the 60s. ReplyAmgen: Lost in the Biotech Bargain Bin [view article]
Have you read any of the news lately on Amgen's top drugs? Billions of dollars of Aranesp sales are now at risk due to gov't restrictions on use of the drug. It will only get worse for Amgen before it gets any better. mark my words, this is definitely a company not to invest in anytime soon. ReplyAmgen: Lost in the Biotech Bargain Bin [view article]
I agree amgn is undervalued by any measure. It has massive free cash flows and a lot of cash (& equivalents) on the balance sheet. The low valuation is likely to attract predetors (i.e. Pfizer) which is sitting on a lot of cash as well. ReplyAmgen: Lost in the Biotech Bargain Bin [view article]
AMGNS FUTURE EARNINGS ARE VERY MUCH IN DOUBTAS IS THE P/E
AMGN TODAY IS NOT THE SLAM DUNK IY WAS YESTERDAY
JTKSR1 Reply
Amgen: Lost in the Biotech Bargain Bin [view article]
What significant drugs does AMGN have in its pipeline?Reply
Amgen: Lost in the Biotech Bargain Bin [view article]
Two problems with your analysis:1) Amgen's future revenues will not be as predictable as they have been in the past.
2) P/E ratios for the markets are very high compared to historical levels. Due to the recession and the deflationary credit crisis, P/E ratios are headed down from the 20's to something more like 8-12.
Either way, Amgen is not the screaming buy you imply that it is.
Vinz Reply